Where Prostate Cancer Spreads In the Body Affects Survival Time
Contact: Sarah Avery Phone: 919-660-1306 Email: sarah.avery@duke.edu https://www.dukehealth.org
EMBARGOED FOR RELEASE until 4 p.m. (ET) on Monday, March 7, 2016
DURHAM, N.C. -- Patients with lymph-only metastasis have the longest overall survival, while those with liver involvement fare worst. Lung and bone metastasis fall in the middle.
“Smaller studies had given doctors and patients indications that the site of metastasis in prostate cancer affects survival, but prevalence rates in organ sites were small, so it was difficult to provide good guidance,” said Susan Halabi, Ph.D., professor of biostatistics at Duke and ...
Source: DukeHealth.org: Duke Health Features - March 8, 2016 Category: Pediatrics Tags: Duke Medicine Source Type: news
Combo Tx Boosts PFS in Urothelial Cancer (CME/CE)
(MedPage Today) -- Progression slowed by half with docetaxel and anti-VEGF agent (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 3, 2016 Category: Hematology Source Type: news
How and When Does Taxotere (Docetaxel) Work to...
Taxotere (docetaxel) is a drug used in men whose prostate cancer no longer responds to hormone therapy. (Source: About.com Prostate Cancer)
Source: About.com Prostate Cancer - January 26, 2016 Category: Cancer & Oncology Tags: health Source Type: news
Athenex Announces US FDA Allowance of the Investigation New Drug Application of Oradoxel, the Proprietary Oral Form of Docetaxel
BUFFALO, N.Y. and HONG KONG, Jan. 25, 2016 -- (Healthcare Sales & Marketing Network) -- Athenex, Inc. announced today that it has received United States Food and Drug Administration (US FDA) allowance to proceed in the clinic with its proprietary oral for... Biopharmaceuticals, Oncology, FDAAthenex, Docetaxel, Orascovery (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 25, 2016 Category: Pharmaceuticals Source Type: news
Even After Anti-Androgen Therapy, Docetaxel Remains Useful in Prostate...
University of Colorado Cancer Center and collaborating institutions present results at 2016 Genitourinary Cancers Symposium showing that 40 percent of patients with castration-resistant metastatic...(PRWeb January 12, 2016)Read the full story at http://www.prweb.com/releases/2016/01/prweb13159325.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 14, 2016 Category: Pharmaceuticals Source Type: news
Even after anti-androgen therapy, docetaxel remains useful in prostate cancer
40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 11, 2016 Category: Science Source Type: news
Even after anti-androgen therapy, docetaxel remains useful in prostate cancer
(University of Colorado Anschutz Medical Campus) A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 10, 2016 Category: Cancer & Oncology Source Type: news
Quality of Life With Docetaxel and ADT in Prostate CancerQuality of Life With Docetaxel and ADT in Prostate Cancer
When docetaxel is added to androgen-deprivation therapy, patients with metastatic prostate cancer report no long-term effects on quality of life. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 8, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Teikoku Pharma USA, Inc. Announces FDA Approval of Docetaxel Injection, Non-Alcohol Formula
San Jose, Calif. - December 28, 2015 - Teikoku Pharma USA (TPU) announced today that the U.S. Food and Drug Administration ("FDA") has approved Docetaxel Injection, Non-Alcohol Formula ("Docetaxel Injection") for the treatment of breast cancer,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 28, 2015 Category: Drugs & Pharmacology Source Type: news
In clinical trial, immunotherapy more effective than chemo in treating advanced lung cancer
A study led by UCLA’s Dr. Edward Garon has found an immunotherapy drug to be more effective than chemotherapy in treating people with advanced lung cancer. The study also showed that the drug, pembrolizumab, was effective in a wider population of people than previously thought.
Researchers compared pembrolizumab to the chemotherapy drug docetaxel in a clinical trial involving more than 1,000 people with PD-L1–expressing non-small cell lung cancer. Patients receiving the immunotherapy lived longer than those who received chemotherapy, said Garon, the study’s senior author and a researcher at the UCLA Jonsson Compreh...
Source: UCLA Newsroom: Health Sciences - December 22, 2015 Category: Universities & Medical Training Source Type: news
New prostate cancer treatment can extend life if given as soon as diagnosis
A landmark study published last night reported that men with advanced prostate cancer lived an average 15 months longer if given docetaxel as soon as they were diagnosed. (Source: the Mail online | Health)
Source: the Mail online | Health - December 22, 2015 Category: Consumer Health News Source Type: news
Study Shows Abiraterone Acetate is Useful Even in Most Aggressive Prostate Cancers; University of Colorado Cancer Center
In 1,048 prostate cancer patients previously treated with docetaxel and 996 metastatic, castration-resistant patients, treatment with the androgen-lowering drug abiraterone acetate led to longer overall disease control, even when a very high Gleason score indicated especially aggressive cancer. Results recently published in the Annals of Oncology show that for patients with Gleason score greater than 8, post-docetaxel treatment with abiraterone extended progression-free survival from 5.5 months ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 3, 2015 Category: Cancer & Oncology Source Type: news
Teikoku Pharma USA and Eagle Pharmaceuticals Enter into License Agreement for Docetaxel, Non-Alcohol Formula
SAN JOSE, Calif., Oct. 15, 2015 -- (Healthcare Sales & Marketing Network) -- Teikoku Pharma USA Inc. ("TPU") today announced that it has entered into an exclusive license agreement with Eagle Pharmaceuticals, Inc. to market, sell, and distribute... Biopharmaceuticals, Oncology, LicensingTeikoku Pharma, Eagle Pharmaceuticals, Docetaxel (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 15, 2015 Category: Pharmaceuticals Source Type: news
Thousands of men with prostate cancer are denied life-giving drug
The drug, docetaxel, is given in Scotland as soon as prostate cancer starts to spread, but in England it is offered at a later stage. The difference means an English sufferer is denied 22 months of life. (Source: the Mail online | Health)
Source: the Mail online | Health - October 5, 2015 Category: Consumer Health News Source Type: news
Medical News Today: Study finds drug improves survival for patients with non-small cell lung cancer
A new phase 3 trial finds that overall survival is longer for patient with non-small cell lung cancer treated with the drug nivolumab compared with chemotherapy drug docetaxel. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 28, 2015 Category: Consumer Health News Tags: Lung Cancer Source Type: news
